Subtype
Colorectal Adenocarcinoma
CI-CAN-00005002Explore in graph →
114 active trials1 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005002Explore in graph →
Clinical trials
367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (54)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Nov 21, 2024 | clinicaltrials |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer(PRIMIER) | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00003486 | Antineoplaston Therapy in Treating Patients With Colon Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2024source: clinicaltrials